Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16
Key Highlights
- ➤Eight treated patients remain alive; median overall survival not reached
- ➤Six evaluable patients achieved 100% objective response under RANO criteria
- ➤Five patients achieved complete responses; one had a 58% tumor reduction
- ➤Alpha DaRT source deployment succeeded in all eight patients, with no unanticipated SAEs
- ➤REGAIN trial plans enrollment of up to 20 recurrent glioblastoma patients
Expert Statements
Uzi Sofer, CEO of Alpha Tau
“In May we shared the first three patients treated with Alpha DaRT in the brain. Six months later, we see how truly transformational Alpha DaRT could be for recurrent GBM. Eight patients have been treated, every procedure has gone as planned, and every one of those patients is alive. The trial thus far has exceeded our wildest expectations, particularly in such a difficult cancer. Glioblastoma is one of the most devastating diagnoses in oncology, and recurrence is virtually inevitable. We look forward to following these patients’ progress as their scans mature, and to continuing enrollment toward 20 patients, which we believe, based on initial discussions, may support market submission requirements for Alpha DaRT in patients with this disease.”
Joshua D. Palmer, MD, Principal Investigator and Radiation Oncologist at the OSUCCC - James
“I am even more encouraged by this newer set of interim results from the REGAIN trial, because we are now beginning to see survival. In recurrent glioblastoma, every patient who reaches six, nine and twelve months makes the picture more compelling, and all of our patients are alive. We have seen responses in every patient who has reached assessment, and have seen no definitive tumor regrowth in the area we treated. We are excited to continue to follow along these patients’ treatment journeys and to treat additional patients in the coming months.”
Robert Den, Chief Medical Officer of Alpha Tau
“The primary endpoints of this trial are feasibility and safety, and on both the data are consistent across all eight patients: every treatment was done as planned, and there have been no unanticipated serious adverse events. The response and survival data are incredibly encouraging for such a difficult disease, and longer follow-up will continue to be of interest in understanding the durability of these responses as we continue to enroll the study.”
- All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median overall survival has not been reached, with a median follow-up of 6.9 months from trial enrollment (range 3.1 to 11.6 months) in the six patients who have reached response assessment -
- All six patients who have reached response assessment achieved a RANO objective response as their best overall response, with five patients showing complete responses (83.3%), including a previously reported stable disease, and one patient with a partial response (16.7%) with a 58% decrease in tumor measurements -
Get started
Create a free account to read the full story.
